渤健|速递|开发创新眼科基因疗法,ViGeneron与渤健达成全球性合作协议( 二 )


About ViGeneron
ViGeneron is dedicated to developing innovative gene therapies to treat ophthalmic diseases with high unmet medical need, as well as partnering with leading biopharmaceutical players in other disease areas. The company’s pipeline is built on two proprietary adeno-associated virus (AAV) technology platforms. The first, vgAAV gene therapy vector platform, allows superior transduction efficiency and intravitreal, a less invasive treatment administration. The second, REVeRT vector platform, targets diseases caused by mutations in large genes. Privately-owned ViGeneron was founded in 2017 by a seasoned team with in-depth experience in AAV vector technology and clinical ophthalmic gene therapy programs and is located in Munich, Germany. For further information, please visit www.vigeneron.com.
注:本文旨在介绍医药健康研究,不是治疗方案推荐 。如需获得治疗方案指导,请前往正规医院就诊 。

推荐阅读